Q-omics provides the consensus-scored ZDHHC1 profile across patient tissues and cancer cell-line models. ZDHHC1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZDHHC1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZDHHC1 RNA expression shows 18,229 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, COAD, and KIRP as cancer lineages where ZDHHC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC1 survival associations across molecular data types. ZDHHC1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC1 RNA expression–survival associations across cancer types. High ZDHHC1 expression shows unfavorable associations in BLCA, LGG and MESO, but favorable associations in UCEC, PAAD and KICH. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZDHHC1 RNA expression.
This table summarizes ZDHHC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC1 shows lower tumor expression in BLCA, THCA, LUAD and UCEC and higher tumor expression in COAD and HNSC. The COAD box plot shows higher ZDHHC1 RNA expression in tumor versus normal tissue (log2 FC = +1.198, t-test p < 0.001).
This table shows molecular features associated with ZDHHC1 in patient tissues and cancer cell lines. In patient samples, ZDHHC1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
